NS-3 (CG3703), an analog of thyrotropin-releasing hormone, ameliorates cognitive impairment in rats.
The effects of thyrotropin-releasing hormone (TRH) and its analog, N-[[(3R,6R)-6-methyl-5-oxo-thiomorpholinyl] carbonyl]-L-histidyl-L- prolinamide tetrahydrate (NS-3, CG3703) on disturbance of memory of a passive avoidance response (PAR) and an escape response in rats were investigated. NS-3 improved amnesia caused by scopolamine, electroconvulsive shock (ECS), and cycloheximide (CXM), but TRH improved only the ECS-induced amnesia. NS-3 reversed learning deficits caused by hypercapnia, but TRH had no effect. These differences in the effect between NS-3 and TRH may be due to their biological half-life in rat plasma. These results suggest that NS-3 possesses more potent antiamnestic effects than TRH in rats.
Ogasawara
T
T
Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Japan.
Ukai
Y
Y
Tamura
M
M
Kimura
K
K
D000595:Amino Acid Sequence; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D003513:Cycloheximide / Q000037:antagonists & inhibitors; D004597:Electroshock; D006935:Hypercapnia / Q000150:complications / Q000188:drug therapy; D008297:Male; D008969:Molecular Sequence Data; D051381:Rats; D017208:Rats, Wistar; D012601:Scopolamine / Q000037:antagonists & inhibitors; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*
C031926:montirelin; D013973:Thyrotropin-Releasing Hormone; D003513:Cycloheximide; D012601:Scopolamine